Compare BioNTech SE - ADR (BNTX) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs SMX Security Matters plc — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while SMX Security Matters plc trades at $16.16 (market cap $17.04M). The key difference: BioNTech SE - ADR is far larger — about 1368× SMX Security Matters plc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| BNTX | SMX | |
|---|---|---|
Market Cap | $23.31B | $17.04M |
Sector | Health | Technology |
52-Week High | $119.34 | $103.71K |
52-Week Low | $83.89 | $12.87 |
Enterprise Value | $6.60B | -$14.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
SMX (Security Matters) trades at $16.16, up 2.28% on the day, but technical indicators signal a bearish trend with the stock near its pivot point. The company reported a net loss of $169.18M for 2025, with negative profitability metrics (ROE -819.22%), though recent news highlights a strengthened balance sheet and progress in commercializing its materials traceability platform amid growing regulatory demand for recycled plastics.
The outlook remains high-risk given persistent losses and cash burn, offset by potential from regulatory tailwinds in recycling. Investors face significant execution risk, but the company's niche in material verification could capture value if commercialization accelerates. The stock's viability hinges on reversing operational losses and achieving sustainable revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
